ROCKVILLE, Md. & SHANGHAI, July 20, 2026
AbelZeta Pharma, Inc. has achieved a significant regulatory milestone after the European Medicines Agency (EMA) granted PRIority MEdicines (PRIME) designation to its investigational C-CAR168 therapy for the treatment of refractory Systemic Lupus Erythematosus (SLE), with or without Lupus Nephritis (LN). The designation represents one of the first major regulatory recognitions of a CAR-T therapy for lupus, underscoring the growing potential of cell therapy beyond oncology and into autoimmune diseases. C-CAR168 is an innovative autologous dual-target anti-CD20/BCMA CAR-T therapy designed to eliminate both disease-causing B cells and antibody-producing plasma cells responsible for chronic autoimmune activity. The PRIME designation provides enhanced regulatory guidance and accelerated development support from the EMA, reinforcing the therapy’s potential to address the substantial unmet medical needs of patients suffering from severe, treatment-resistant lupus while advancing AbelZeta’s global strategy to expand next-generation CAR-T therapies into immune-mediated disorders.
EMA PRIME Validates AbelZeta’s Dual-Target CAR-T Innovation
The EMA PRIME designation recognizes medicines that demonstrate the potential to provide significant therapeutic advantages for conditions with limited treatment options. For AbelZeta, this recognition validates years of research focused on applying dual-target CAR-T technology to autoimmune diseases. Unlike conventional therapies that primarily suppress immune activity, C-CAR168 has been specifically engineered to target both CD20-positive B cells and BCMA-positive plasma cells, two critical drivers of autoimmune disease progression. By simultaneously eliminating these pathogenic immune cell populations, the therapy aims to achieve a deeper and more durable immune system reset, potentially allowing patients to experience long-lasting disease remission while reducing dependence on chronic immunosuppressive medications. The PRIME designation also enables earlier scientific dialogue with European regulators, optimized clinical development planning, and the possibility of accelerated regulatory review, strengthening AbelZeta’s pathway toward future commercialization across international markets.
C-CAR168 Advances Global Development for Lupus
The latest European regulatory recognition builds upon earlier momentum achieved in the United States. In May 2025, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to C-CAR168 for patients with refractory Systemic Lupus Erythematosus, including those affected by Lupus Nephritis. Together, the FDA RMAT and EMA PRIME designations provide strong validation from two of the world’s leading regulatory agencies, highlighting the therapy’s potential to transform treatment for patients with severe autoimmune disease. Systemic Lupus Erythematosus remains a chronic inflammatory disorder capable of damaging multiple organs, while Lupus Nephritis, one of its most serious complications, can lead to progressive kidney failure despite existing treatment options. Patients with refractory disease continue to experience persistent inflammation, cumulative organ damage, and long-term complications associated with prolonged immunosuppressive therapy, emphasizing the urgent need for innovative treatment approaches capable of delivering sustained clinical benefit.
Advertisement
AbelZeta Expands CAR-T Beyond Oncology
The EMA PRIME designation further strengthens AbelZeta Pharma’s position as an emerging leader in cell therapy innovation. Headquartered in Rockville, Maryland, and Shanghai, the clinical-stage biopharmaceutical company continues to develop a growing portfolio of CAR-T therapies targeting not only hematologic malignancies but also autoimmune diseases, inflammatory disorders, and solid tumors. Through its advanced GMP manufacturing facilities, AbelZeta is accelerating global development of proprietary cell-based therapies designed to harness the body’s immune system for precision treatment. The company’s strategy reflects the broader evolution of CAR-T technology, which is rapidly expanding beyond cancer into diseases driven by immune dysfunction. With both EMA PRIME and FDA RMAT designations supporting C-CAR168, AbelZeta is well positioned to advance one of the most promising investigational therapies for refractory lupus, potentially delivering a transformative treatment option capable of redefining the future of autoimmune disease management.
Source: AbelZeta Pharma press release
